Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

NVAX stock has risen nearly 10% in the past five trading sessions on expectations that the FDA is going to approve its Covid-19 vaccine. The post Novavax (NVAX) Stock Pops Ahead of FDA Approval appeared first on InvestorPlace.

Novavax (NVAX) Stock Pops Ahead of FDA Approval

The shares of Novavax, Inc. (NASDAQ:NVAX) are up 2.2% at $71.30 this morning, after Politico reported that the pharmaceutical company's two-dose Covid-19 vaccine could receive approval from the U.S. Food and Drug Administration (FDA) as soon as today.

Potential FDA Approval for Novavax Vaccine Sends Stock Even Higher

NVAX stock looks due for a bounce-back as Novavax makes strides in providing Covid-19 vaccines in the U.S. and internationally. The post More Vaccine Jabs Means Novavax Stock Is Up for Grabs appeared first on InvestorPlace.

More Vaccine Jabs Means Novavax Stock Is Up for Grabs

Regulatory clearance of the two-dose shot for adults could come as early as Wednesday, according to a Politico report.

Novavax Stock Rises as FDA Looks Poised to Clear Covid-19 Vaccine

A media report says that the company's coronavirus vaccine is about to be authorized for use in the U.S.

Why Novavax Stock Shot Higher Today

Novavax (NVAX) inks a deal with the US government to supply 3.2 million doses of COVID shot. But the deal will be effective only if the vaccine gets EUA from the FDA.

Novavax (NVAX) Inks COVID Jab Supply Deal With US Government

Coinbase

Vir Biotechnology

COVID fighters and crypto brokers are super-cheap right now.

3 Cheap Stocks To Buy Now

The beaten-down vaccine stock's recent rebound could be just the beginning.

Novavax Stock Is Sizzling Hot Once Again -- Time to Buy?

Moderna

Pfizer

This article will compare Pfizer, Moderna, and Novavax to see which of these coronavirus stocks will yield the highest returns. The post Which Coronavirus Stock Could Fetch Higher Returns?

Which Coronavirus Stock Could Fetch Higher Returns?

The vaccine, which differs from mRNA shots like Pfizer's and Moderna's, still needs FDA emergency authorization before it can be administered.

U.S. Secures 3.2 Million Novavax Covid Vaccines — Offering Alternative To MRNA Shots As New Variant Spreads

Novavax Inc (NASDAQ: NVAX) has announced an agreement with the U.S. Department of Health and Human Services, in collaboration with the Department of Defense, to secure an initial 3.2 million doses of its COVID-19 vaccine. The agreement is conditional on receiving FDA Emergency Use.

US Government Signs COVID-19 Vaccine Pact With Novavax, With FDA Decision Still Pending

The U.S. government purchased 3.2 million doses of Novavax Inc.'s still-investigational COVID-19 vaccine. Novavax's recombinant protein-based vaccine uses different technology than the mRNA shots developed by Moderna Inc. and BioNTech SE.

U.S. to buy 3.2 million doses of Novavax's COVID-19 vaccine if authorized

Agreement will provide the first protein-based vaccine option in the U.S., pending FDA Emergency Use Authorization and CDC recommendation GAITHERSBURG, Md. , July 11, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced an agreement with the U.S. Department of Health and Human Services (HHS), in collaboration with the Department of Defense, to secure an initial 3.2 million doses of Novavax' COVID-19 vaccine (NVX-CoV2373) should it receive U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) and a recommendation from the Centers for Disease Control and Prevention (CDC).

U.S. Government Secures 3.2 Million Doses of Novavax COVID-19 Vaccine

Adaptive Biotechnologies

Beam Therapeutics

Vertex Pharmaceuticals

Check these health care stocks out for your watchlist right now

Top Health Care Stocks To Buy Right Now? 4 To Watch

FDA's advisory committee supports granting authorization to Novavax's (NVAX) COVID-19 vaccine for use in adults. The vaccine also receives authorization for use in adolescents in Europe.

Novavax (NVAX) Stock Rallies 26.8% in a Month: Here's Why

The company is granted an important expansion of a CMA, however.

Why Novavax Stock Lagged the Market on Wednesday

Novavax (NVAX) obtains EU approval for its Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17.

Novavax (NVAX) COVID Jab Receives EU Nod for Adolescents

Biotech company Novavax said it expects to be able to provide an Omicron-targeting vaccine in the fourth quarter of this year. Its vaccine is under FDA review.

Novavax expects Omicron-targeting vaccine by fourth quarter

Novavax (NVAX) stock is taking off on Tuesday after the vaccine company got approval for the expanded use of its Covid-19 vaccine in Europe. The post Why Is Novavax (NVAX) Stock Rallying Today?

Why Is Novavax (NVAX) Stock Rallying Today?

Its vaccine notched another expansion of its conditional approval in Europe.

Why Novavax Stock Got a Boost Today

Shares of Novavax Inc. NVAX, +5.74% surged 4.4% toward a two-month high in morning trading Tuesday, to buck the selloff in the broader stock market, after the biotechnology company said its COVID-19 vaccine Nuvaxovid received expanded conditional marketing authorization (CMA) from the European Commission (EC) for people aged 12 through 17. Novavax's COVID vaccine has not yet been authorized for use in the U.S., and the trade name Nuvaxovid has not yet been approved by the U.S. Food and Drug Administration.

Novavax stock rallies after EU expands CMA on COVID vaccine for 12 to 17-year olds

Nuvaxovid™ COVID-19 vaccine is the first protein-based option for adolescents aged 12 through 17 in Europe GAITHERSBURG, Md. , July 5, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Commission (EC) has approved the expanded conditional marketing authorization (CMA) of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine in the European Union (EU) for adolescents aged 12 through 17.

Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17

Interest around the potential for another Covid-19 surge this winter, as well as vaccine efficacy, has NVAX stock soaring today. The post Why Is Novavax (NVAX) Stock Up 10% Today?

News for Novavax Stock (NVAX)